Compare BLRX & CABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLRX | CABR |
|---|---|---|
| Founded | 2003 | 2020 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 12.1M |
| IPO Year | 2010 | N/A |
| Metric | BLRX | CABR |
|---|---|---|
| Price | $2.86 | $0.86 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | 11.2K | ★ 64.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.30 | $0.71 |
| 52 Week High | $7.77 | $1.65 |
| Indicator | BLRX | CABR |
|---|---|---|
| Relative Strength Index (RSI) | 48.37 | 49.40 |
| Support Level | $2.71 | $0.79 |
| Resistance Level | $3.93 | $1.09 |
| Average True Range (ATR) | 0.18 | 0.10 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 46.83 | 56.31 |
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Caring Brands Inc is a consumer wellness company that supports health and wellness through research and development. Its product pipeline addresses a range of conditions, including hair loss, eczema, burns, and sexual wellness. The majority of revenue is generated from the sale of OTC and consumer products, as well as licensing royalties.